scholarly journals Intracranial hemorrhages in children with immune thrombocytopenia

2021 ◽  
Vol 20 (3) ◽  
pp. 92-101
Author(s):  
E. V. Suntsova ◽  
M. N. Sadovskaya ◽  
O. V. Spichak ◽  
S. S. Ozerov ◽  
S. P. Khomyakova ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intracranial Hemorrhage ◽  
Immune Thrombocytopenia ◽  
Scientific Research ◽  
Intracranial Hemorrhages ◽  
Hemorrhagic Complications ◽  
Primary Immune Thrombocytopenia ◽  
Life Threatening ◽  
Clinical Cases

Primary immune thrombocytopenia is a benign and self-limiting process in the majority of children. Severe life-threatening hemorrhages, including intracranial, develop rarely. Risk factors predisposing for development of severe hemorrhagic complications have not been determined. In order to decrease the severity of neurological consequences and mortality in intracranial hemorrhages, timely combined urgent therapy is neсessary. There are four clinical cases of intracranial hemorrhage in immune thrombocytopenia in children with different outcomes in this article. The parents of the patients agreed to use the information, including photos of children, in scientific research and publications.

Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases

2016 ◽  
Vol 91 (12) ◽  
pp. E499-E501 ◽  
Author(s):  
Sara Melboucy‐Belkhir ◽  
Mehdi Khellaf ◽  
Alexandre Augier ◽  
Marouane Boubaya ◽  
Vincent Levy ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intracranial Hemorrhage ◽  
Immune Thrombocytopenia ◽  
Factors Associated

scholarly journals Early Outcome after Intracranial Hemorrhage Related to Non-Vitamin K Oral Anticoagulants

2017 ◽  
Vol 7 (1-2) ◽  
pp. 19-25 ◽  
Author(s):  
Senta Frol ◽  
Janja Pretnar Oblak
Keyword(s):  
Risk Factors ◽  
Intracranial Hemorrhage ◽  
Vitamin K ◽  
Rare Complication ◽  
Oral Anticoagulants ◽  
Clinical Status ◽  
Single Center ◽  
Bleeding Events ◽  
Single Center Study ◽  
Life Threatening

Background: Intracranial hemorrhage (ICH) is a serious, life-threatening, but fortunately rare complication of non-vitamin K oral anticoagulant (NOAC) therapy. There are limited data on NOAC-related ICH prognosis. Methods: All consecutive patients admitted to a single center due to acute NOAC-related ICH from September 2012 until the beginning of 2017 were included. Risk factors, type of NOAC, and location of ICH were evaluated. Risk for ischemic and bleeding events and clinical status upon admission and at discharge were evaluated using standard scales. Results: Thirty-four patients aged 77.8 ± 8.3 years with NOAC-related ICH were included. The main predisposing risk factors were age and arterial hypertension. The median CHA2DS2-VASc score was 3.4 and the median HAS-BLED score was 1.8. Eighteen patients were treated with rivaroxaban, 11 with dabigatran, and 5 with apixaban. Ten patients (29%) had a favorable outcome with a modified Rankin Scale score ≤2 and 13 patients (38%) died. The location of the ICH was mainly intraparenchymal and subdural. Conclusions: Our retrospective single-center study shows that the mortality rate with NOAC-related ICH is <40%, which makes it comparable to that with vitamin K antagonist-related ICH.

scholarly journals Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report

TH Open ◽  
2021 ◽  
Vol 05 (03) ◽  
pp. e315-e318
Author(s):  
Martin Koch ◽  
Sybille Fuld ◽  
Jan M. Middeke ◽  
Julia Fantana ◽  
Simone von Bonin ◽  
...  
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Immune Thrombocytopenia ◽  
Coagulation Disorders ◽  
High Efficacy ◽  
Public Attention ◽  
Considerable Potential ◽  
Hemorrhagic Complications ◽  
Life Threatening ◽  
Primary Management

AbstractNovel mRNA and vector-based covid-19 vaccinations have shown high efficacy in preventing symptomatic COVID-19 infections. Compared with the number of performed vaccinations, rates of severe side effects seem low. Rare prothrombotic coagulation disorders with suspected association to ChAdOx1 nCoV-19 (AstraZeneca) have been reported. These cases have gathered considerable media attention and caused a temporary pause of usage of the AstraZeneca vaccine in Europe and several other countries and are currently discussed as vaccine-induced immune thrombotic thrombocytopenia (VITT). However, hemorrhagic complications from ChAdOx1 nCoV-19 vaccination have also been reported but, so far, received less public attention despite considerable potential for life-threatening complications. Here we present a case of severe immune thrombocytopenia after ChAdOx1 covid-19 vaccination and its successful primary management.

Intracranial hemorrhage in primary immune thrombocytopenia (ITP): 20 years’ experience in pediatrics

2021 ◽  
Author(s):  
Mohsen Saleh Elalfy ◽  
Khadiga Yehia Elsayed Mousa Eltonbary ◽  
Islam R. El Ghamry ◽  
Omar Elalfy ◽  
Marwa Wahid ◽  
...  
Keyword(s):  
Intracranial Hemorrhage ◽  
Immune Thrombocytopenia ◽  
Primary Immune Thrombocytopenia

scholarly journals Immune thrombocytopenia and thrombosis. Hematological paradox or clinical reality?

2021 ◽  
Vol 23 (6) ◽  
pp. 463-468
Author(s):  
Leonid I. Dvoretsky ◽  
Keyword(s):  
Risk Factors ◽  
Antiphospholipid Antibodies ◽  
Immune Thrombocytopenia ◽  
Epidemiological Data ◽  
Clinical Situation ◽  
Thromboembolic Events ◽  
Antithrombotic Agents ◽  
Clinical Reality ◽  
Primary Immune Thrombocytopenia ◽  
Platelet Microparticles

One of the features of primary immune thrombocytopenia is the development of thrombosis in patients, the incidence of which exceeds that in the population. The review provides epidemiological data on thromboembolic events, pathogenetic mechanisms and risk factors for their development, therapeutic tactics in this category of patients. In patients with immune thrombocytopenia, the following factors are important for the development of thromboembolic events: the pathogenetic features of the disease itself (increased functional activity of young platelets, platelet microparticles, antiphospholipid antibodies, activation of complement, an increase in the level of procoagulants, a decrease in the activity of ADAMTS13), the presence of comorbid risk factors for thrombosis, thrombogenic adverse effects of drugs used to treat immune thrombocytopenia. Therapeutic tactics of managing patients with immune thrombocytopenia who develop thromboembolic events consists in correcting the number of platelets (glucocorticoids, intravenous immunoglobulin) and administration of antithrombotic agents, given the clinical situation and the number of platelets.

Sign in / Sign up

Export Citation Format

Share Document